The Readout Loud

373: Party in biotech land and AstraZeneca’s miscalculation

372: A pharma C-suite shakeup and Trump's deal with Pfizer

371: A gene therapy success in Huntington's and Trump's autism announcement

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

369: Trump, Chinese biotech, and an industry career reshaped by illness

368: New stakes in the vaccine dispute and a boost for biotech

367: The ouster of CDC's director, biotech venture firm rankings

366: Viking’s obesity flop, ‘pharma to table’ drug sales

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

363: What Vinay Prasad’s ouster means for biotech and the FDA

362: A mother’s perspective on Sarepta’s gene therapy halt

361: Inside an FDA drug rejection, and layoffs at Sarepta

360: NIH grant cuts, FDA transparency questions and biotech M&A

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

358: FDA's gene therapy turmoil, and an alternative model for funding research

357: The upheaval of CDC's vaccine panel, and drug pricing confusion

356: An AI experiment at the FDA & Novo trailing in the obesity drug race

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview

354: Uncertainty in CRISPR world and the start of more M&A

353: Trump's drug-pricing plan and a potential Theranos 2.0

352: A firebrand takes oversight of vaccines, gene therapies

351: It's gonna be May (in biotech)

350: Pharma tariffs, and a 'sunshine day' for biotech stocks

349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

348: Cuts, ousters and drama at the FDA

347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival

346: Zealand's obesity strategy and Immunovant's curious development plan

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

344: Trump's FDA commissioner nominee takes the hot seat

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

342: FDA cuts, zombie biotechs, and too much weight loss?

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

From Tradeoffs: Race to the Bottom